PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) announced new real-world effectiveness data for its RSV vaccine, AREXVY, showing an association with reduced RSV-related hospitalizations in adults 60 and older. AREXVY ...
2026 Copyright © News-Matic.com. All Rights Reserved
